Duncan H. Mak

Department of Hematopoietic Biology & Malignancies, The University of Texas MD Anderson Cancer Center

Affiliated withThe University of Texas MD Anderson Cancer Center

Research Area

Biography

Duncan H. Mak has not added Biography.
If you are Duncan H. Mak and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title	2025

Other Publications

Article	Year
Regulation and targeting of Eg5, a mitotic motor protein in blast crisis CML: overcoming imatinib resistance. Cell cycle (Georgetown, Tex.)\| PubMed ID: 16969080	2006
MRx102, a triptolide derivative, has potent antileukemic activity in vitro and in a murine model of AML. Leukemia\| PubMed ID: 21904380	2012
Activation of apoptosis signaling eliminates CD34+ progenitor cells in blast crisis CML independent of response to tyrosine kinase inhibitors. Leukemia\| PubMed ID: 22033489	2012
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML. Blood\| PubMed ID: 22645176	2012
Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid ... British journal of haematology\| PubMed ID: 25079338	2014
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry. Part A : the journal of the International Society for Analytical Cytology\| PubMed ID: 25598437	2015
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells. Oncotarget\| PubMed ID: 26431162	2015
Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget\| PubMed ID: 26956049	2016
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells. Oncotarget\| PubMed ID: 27391151	2016
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells. Science translational medicine\| PubMed ID: 27605552	2016
Focal Adhesion Kinase as a Potential Target in AML and MDS. Molecular cancer therapeutics\| PubMed ID: 28270436	2017
Rapid monoisotopic cisplatin based barcoding for multiplexed mass cytometry. Scientific reports\| PubMed ID: 28630464	2017
Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy. Oncotarget\| PubMed ID: 29228548	2017
Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition in -Mutant Acute Myeloid Leukemia. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 29463558	2018
Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica\| PubMed ID: 31123034	2020
Antileukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Molecular cancer therapeutics\| PubMed ID: 31227645	2019
Combined inhibition of MDM2 and BCR-ABL1 tyrosine kinase targets chronic myeloid leukemia stem/progenitor cells in a murine model. Haematologica\| PubMed ID: 31371419	2020
Maximal Activation of Apoptosis Signaling by Cotargeting Antiapoptotic Proteins in BH3 Mimetic-Resistant AML and AML Stem Cells. Molecular cancer therapeutics\| PubMed ID: 35364607	2022
Inhibition of menin, BCL-2, and FLT3 combined with a hypomethylating agent cures -ITD/-TKD mutant acute myeloid leukemia in a patient-derived xenograft model. Haematologica\| PubMed ID: 36727398	2023
Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies. Science translational medicine\| PubMed ID: 37163614	2023